Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. freshman Avg
|
|
New words:
Abbivie, abbreviated, AbbVie, abstr, abuse, adapt, added, al, Albert, ASH, ASU, Atomic, Atossa, attend, attended, attorney, Baylor, BeginningJanuary, biosimilar, BPCIA, brand, branded, clarify, cleanup, Clin, collateral, College, Columbia, comment, complicating, comprising, conduit, Congressional, credible, CRO, curtailment, cytoreduction, dealt, debated, deducting, defraud, denial, depriving, distinction, DOTA, DSMB, Edison, Einstein, establishedin, exposed, feasibility, float, footnote, fraudulent, function, GAAP, gap, GBH, GCP, Glioblastoma, guidance, guiding, headcount, higher, hinder, HIPAA, HITECH, hurt, implanted, imprisonment, incidence, infused, inhaled, inhibit, inInternal, injected, instilled, interchangeable, interrupt, intrinsic, ix, jeopardized, JG, Jurcic, McDevitt, meantime, Med, methodology, misuse, MLV, monotherapy, multi, Multiforme, myloma, nanocurie, nonclinical, Oncol, orientation, outpatient, pain, paragraph, pathway, physicochemical, pollution, Portability, Postgrad, potency, Prepaid, prescription, privacy, qualitative, questioned, rare, rebate, reexamination, referral, repeat, resubmit, Rosenblat, salvage, scheme, science, send, Sequential, shelf, shortage, statute, stay, stopped, store, strict, sublease, sublicense, subsection, Subtopic, sued, sunshine, superior, suppl, teaching, tenant, Thornall, ticker, TL, transmission, Tumor, unannounced, undepreciated, Undesirable, unforeseen, unqualified, unreliable, varying, VIE, vii, viii, vitro, waste, wealth, willfully, worldwide, wrote, yearly, Yeshiva
Filing tables
Filing exhibits
- 10-K Annual report
- 3.7 Certificate of Amendment
- 10.42 Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Stock Plan.
- 10.43 Consulting Agreement
- 10.44 Actinium Pharmaceuticals, Inc. Amended and Restated 2013 Equity Incentive Plan.
- 21.1 List of Subsidiaries
- 23.1 Accountant's Consent
- 31.1 Certification
- 31.2 Certification
- 32.1 Certification
- 32.2 Certification
- Download Excel data file
- View Excel data file
ATNM similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER, PURSUANT TO
18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Actinium Pharmaceuticals, Inc. a Delaware corporation (the “Company”), on Form 10-K for the period ended December 31, 2014 as filed with the Securities and Exchange Commission (the “Report”), I, Kaushik J. Dave, President and Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Kaushik J. Dave
Kaushik J. Dave
President and Chief Executive Officer
(Principal Executive Officer)
Date: March 16, 2015